{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:52:44Z","timestamp":1777452764753,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T00:00:00Z","timestamp":1363824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:p>\n                    Phosphate binders have traditionally been used to treat hyperphosphatemia, a common complication in patients with end stage renal disease (\n                    <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>\n                    ). New evidence suggests that nicotinic acid and its metabolites may effectively decrease phosphorus absorption in the gastrointestinal tract, thereby reducing serum phosphorus concentrations. We conducted a literature search to identify studies of patients with\n                    <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>\n                    on dialysis that evaluated the role of niacin and related compounds in decreasing serum phosphorus levels. We searched PubMed using the search terms niacin, nicotinic acid, niacinamide, nicotinamide and hyperphosphatemia. Limits were set to include only those articles published since 2002, conducted in human subjects, and written in the English language. Review articles captured through this process were mined for references to other primary literature that may not have been returned through the initial search. All studies were included if they met the search criteria and were conducted in patients with\n                    <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>\n                    who received either hemodialysis or peritoneal dialysis. To identify current, ongoing studies, another search was conducted through clinicaltrials.gov. Among the seven studies that met our exclusion criteria, three used nicotinic acid as the therapeutic intervention and four used nicotinamide. Both nicotinic acid and nicotinamide were effective in significantly reducing serum phosphorus concentrations in patients with\n                    <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>\n                    on either hemodialysis or peritoneal dialysis. Additional, large\u2010scale studies that assess the appropriate dose as well as long\u2010term safety and efficacy are recommended before clinicians can confirm their place in therapy.\n                  <\/jats:p>","DOI":"10.1002\/phar.1258","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T19:58:06Z","timestamp":1363982286000},"page":"683-690","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Nicotinic Acid and Nicotinamide: A Review of Their Use for Hyperphosphatemia in Dialysis Patients"],"prefix":"10.1002","volume":"33","author":[{"given":"Amanda","family":"Rennick","sequence":"first","affiliation":[{"name":"Purdue University College of Pharmacy West Lafayette Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Kalakeche","sequence":"additional","affiliation":[{"name":"IU Health Arnett Nephrology Lafayette Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Seel","sequence":"additional","affiliation":[{"name":"Purdue University College of Pharmacy West Lafayette Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Shepler","sequence":"additional","affiliation":[{"name":"Purdue University College of Pharmacy West Lafayette Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.09500.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000038685.95946.83"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.12.025"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.3.610"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2550185"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.5.1195"},{"key":"e_1_2_5_8_1","first-page":"F15","article-title":"Nicotinamide as a rapid\u2010acting inhibitor of renal brush\u2010border phosphate transport","volume":"2","author":"Wu KI","year":"1988","journal-title":"Am J Physiol"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh781"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.12.015"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-011-0212-1"},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/ajhp\/60.suppl_2.S9","article-title":"Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety","volume":"60","author":"Peiper JA","year":"2003","journal-title":"Am J Health\u2010Syst Pharm"},{"key":"e_1_2_5_13_1","volume-title":"Drug Point Summary","author":"Niacin"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP45448"},{"key":"e_1_2_5_15_1","unstructured":"National Institutes of Health.Nicotinamide in Hemodialysis Patients with Hyperphosphatemia (DONATO). Available at:http:\/\/clinicaltrials.gov. Accessed May 31 2012."},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00482.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-006-0001-x"},{"key":"e_1_2_5_18_1","unstructured":"SampathkumarK SoorajY MahaldarA.Comparative efficacy of low dose nicotinic acid and lanthanum in lowering the phosphorus levels in hemodialysis patients. Paper presented at World Conference on Nephrology 2007 Rio de Janeiro Brazil."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01470307"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04211007"},{"issue":"1","key":"e_1_2_5_21_1","first-page":"61","article-title":"Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia","volume":"28","author":"Valencia CA","year":"2008","journal-title":"Nefrologia"},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","article-title":"The effect of oral niacinamide on plasma phosphorus concentrations in peritoneal dialysis patients","volume":"29","author":"Young DO","year":"2009","journal-title":"Perit Dial Int"},{"issue":"1","key":"e_1_2_5_23_1","first-page":"58","article-title":"Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double blind randomized clinical trial","volume":"31","author":"Shahbazian H","year":"2011","journal-title":"Nefrologia"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.308"},{"key":"e_1_2_5_25_1","volume-title":"Altas of CKD and ESRD 2012. United States renal data systems","author":"USRDS"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.192"},{"key":"e_1_2_5_27_1","volume-title":"Drug point summary","author":"Niacinamide"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00952-7"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.2012.00479.x"},{"key":"e_1_2_5_30_1","volume-title":"Red book online","author":"Renvela"},{"key":"e_1_2_5_31_1","volume-title":"Red book online","author":"Niacin"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1258","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:10:07Z","timestamp":1761070207000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1002\/phar.1258"],"URL":"https:\/\/doi.org\/10.1002\/phar.1258","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,21]]},"assertion":[{"value":"2013-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}